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INTRODUCTION
Small -cell lung cancer (SCLC) accounts for 15-20% of lung can-
cer (1) and presents aggressive clinical behavior characterized by
rapid growth, metastatic spread to the distant organs (2). Despite
the high response rate to initial chemotherapy, most patients sub-
sequently experience a relapse of the primary tumor or distant me-
tastasis, and the prognosis is still poor. SCLC is clinically catego-
rized as two stages, limited disease (LD) and extensive disease
(ED). LD-SCLC is defined as to be confined to the ipsilateral
hemithorax and regional nodes, and able to be included in a single
tolerable radiotherapy port. LD-SCLC is primarily treated with a
combination of chemotherapy and radiotherapy, and its prognosis
is improved by the development novel effective radiation therapy,
such as accelerated hyperfractionated thoracic radiotherapy (AHF-
TRT) (3). On the other hands, for ED-SCLC which is beyond the
boundaries of LD including distant metastases, malignant pericar-
dial, or pleural effusion and contralateral supraclavicular and con-
tralateral hilar involvement, platinum-based combination chemo-
therapy alone is used as the initial therapy (4-6). Despite the several
novel anticancer agents against non-small cell lung cancer were
developed and shown to have favorable outcome, the chemother-
apy regimens against SCLC were not making any progress in recent
decade, which leads to the poor prognosis of ED-SCLC.
In the past, several studies were performed to reveal the prog-
nostic factors in SCLC (7-19). In these studies, male, poor perform-
ance status (PS) and weight loss as the host factors, and the extent
of disease, number of metastatic sites, brain metastasis, bone me-
tastasis, liver metastasis, elevated white blood cell (WBC) counts,
neutrophil counts, serum lactate dehydrogenase (LDH), alkaline
phosphatase (ALP), decreased platelet (PLT) counts, albumin
(ALB), sodium, and C-reactive protein (CRP) as the tumor-related
factors were reported to be unfavorable prognostic factors in mul-
tivariate analysis. Among these factors, existence of distant organ
metastasis become easily a major problem of treatment in clinics,
and metastatic involvement of the central nervous system, the bone
marrow, or the liver is usually unfavorable compared with other
sites.
For the brain metastasis of SCLC, whole brain radiotherapy
(WBRT) was mainly performed currently in the combination with
chemotherapy. Moreover, novel stereotactic irradiation (STI) tech-
niques were developed recently, such as stereotactic radiosurgery
(SRS) or volumetric-modulated arc therapy (VMAT), resulted in
improving the management of adverse events and prognosis (20-
23). For the bone metastasis, not only palliative radiotherapy (24),
but also novel bone modifying agents (BMAs), such as zoledronic
acid or denosumab can be used in recent days (25-26). On the
other hands, we still have few treatment strategies against liver
metastasis, and frequently faced lethal clinical courses of aggres-
sive and uncontrollable liver metastasis.
Given that most of data regarding the prognostic factors in SCLC
were reported in 1980s or 1990s, the prognostic factors might be
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different from previous findings because of recent progress of
novel treatment modalities. Therefore, in this study we analyzed
the prognostic factors of SCLC patients, especially the status of
distant organ metastasis, in recent days.
PATIENTS AND METHODS
Participants
This was a retrospective study to evaluate ED-SCLC patients
who were admitted to Tokushima University Hospital between
March 1, 2010 and June 30, 2016. Totally, 81 patients who were in
extensive stage at diagnosis were enrolled to this study. We ex-
cluded one patient who did not have enough data for the analysis,
and one patient who refused any treatments.
The statement on consent to participate in this study was ob-
tained from patients by written informed consent forms, if appli-
cable, or by the disclosure of information for participation. The study
was performed in accordance with the Declaration of Helsinki and
the study protocol was approved by the Institutional Review Board
of Tokushima University Hospital (approval number : 2366, ap-
proval date : 2015/8/31).
Data collection
We collected several pretreatment factors, such as age, gender,
performance status (PS), smoking status (Brinkman Index), comor-
bidities in the lungs such as chronic obstructive pulmonary disease
(COPD) or interstitial pneumonia (IP), distant metastatic sites at
diagnosis (brain, bone, liver, adrenal gland, lung, and pleura), and
several laboratory data which were previously reported as prog-
nostic factors of lung cancer. The laboratory data at the start of
treatments were analyzed in this study. We also collected the data
about radiotherapies after BMAs during treatments, the total num-
ber of chemotherapy regimens, and overall survival. The data were
collected retrospectively from the medical records of Tokushima
University Hospital, and in some patients, who moved to other
hospital during treatments, the additional data were supplied from
those hospitals.
Statistical analysis
For univariate analysis, median survival times (MSTs) were
estimated by the Kaplan-Meier method, and statistical analyses
were performed by the Log-rank test (27). The factors which P -
value was0.2 in the univariate analysis, as well as the other clini-
cally important factors, such as distant metastatic sites at diagnosis
and CRP were included in the multivariate analysis. The Cox pro-
portional hazards regression model was used for the multivariate
analysis (28). Clinical parameters and laboratory parameters were
analyzed separately. In the laboratory data, significant correlations
in the Pearson product-moment correlation coefficient were seen
between liver and biliary enzymes, therefore, only ALP, which was
the most significant parameter of the liver and biliary enzymes in
univariate analysis, was induced to the multivariate analysis. The
continuous variables, such as age, PS, and the laboratory data were
categorized according to the previous reports before analysis. The
differences of PS between two groups (with or without distant
metastasis in each organ) were evaluated with Mann-Whitney U
Test. All analysis were performed using EZR (Saitama Medical Cen-
ter, Jichi Medical University, Saitama, Japan), which is a graphical
user interface for R (The R Foundation for Statistical Computing,
Vienna, Austria) (29).
RESULTS
Patient characteristics
Patient characteristics are shown in Table 1. The median age
was 72 years, and 41 patients (52%) were70 years. Most patients
were male (71 patients, 90%), and clinical stage IV (74 patients,
94%), and 52 patients (66%) had PS 0-1. Thirty - three patients (42%)
and 21 patients (27%) were associated with COPD and IP, respec-
tively. The metastasis to the brain (BRA), the bone (OSS), the liver
(HEP), the adrenal glands (ADR) and the lungs (PUL), and the
dissemination in the pleural cavity (PLE) were detected in 38%,
19%, 35%, 20%, 16%, and 25% of the patients at diagnosis, respec-
tively. Four patients (5%) were treated with radical thoracic radio-
therapy (AHF-TRT). Most patients with brain metastasis were
treated with radiotherapy, such as WBRT or STI, and bone metas-
tasis were treated with radiotherapy and BMAs. Most patients were
treated with platinum-based chemotherapeutic regimens, and the
median number of chemotherapy regimens was two. In the labo-
ratory data, hypoalbuminemia and elevation of LDH was seen in
37 (59%) and 56 patients (72%), respectively. The tumor markers
such as Pro-gastrin-releasing peptide (ProGRP) and Neuron-
specific enolase (NSE) were elevated in most patients.
Results of the univariate analysis
The results of the univariate analysis for demographic, clinical,
and laboratory variables are shown in Table 2 and Figure 1. In the
demographic and clinical variables, five of twelve factors were de-
termined to have prognostic significance. Elderly patients (70
years) or the patients with poor PS (PS 2-4) survived shorter than
the others (P0.001). Moreover, IP but not COPD as comorbid
disease was selected as a poor prognostic factor. The prognosis
of patients with liver metastasis was significantly deteriorated com-
pared with those without liver metastasis, while this was not the
case for brain and bone metastasis. We also evaluated the pretreat-
ment laboratory data which are reported to be prognostic factors
in lung cancer patients, such as WBC or neutrophil counts, ALB,
and calcium corrected for albumin (cCa). Among them, elevation
of neutrophil counts, hypoalbuminemia and hypercalcemia were
selected as prognostic factors. Interestingly, the elevation of alanine
amino transferase (ALT), ALP and γ -glutamyl transpeptidase (γ -
GTP), those were thought to be caused by liver metastasis, sig-
nificantly associated with poor prognosis.
Results of the multivariate analysis
The Cox proportional hazard regression analysis was performed
by using variables with P -value was0.2 in the univariate analysis
and other clinically important factors, such as distant metastatic
sites at diagnosis. In this study, we analyzed the significance of clini-
cal parameters and laboratory parameters separately in several rea-
sons. First, only 79 patients were analyzed in this study. Because
the statistical power seems to be dependent on the total number of
events, that is patient’s death, there is a limitation in the number of
parameters to be analyzed in multivariate analysis. Therefore, we
thought it is better to reduce the parameters in multivariate analy-
sis model. Second, there were some correlations between clinical
factors and laboratory factors, such as liver metastasis and the ele-
vation of liver enzymes, therefore we thought it is not better to
induce these correlated parameters in multivariate analysis model
at the same time. When we performed the analysis with only clini-
cal variables, age, PS, IP were determined as independently signifi-
cant poor prognostic factors (Table 3a). The multivariate analysis
of the laboratory data was performed with the essential clinical
variables such as age, gender and PS, and laboratory data which
P -value was0.2 in the univariate analysis. Moreover, since the
significant correlations in the Pearson product-moment correla-
tion coefficient were seen between liver and biliary enzymes, only
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Table 1 Patient characteristics
No. of patients
(n=79) ％
No. of patients
(n=79) ％
Age (years) Platelet count (104/μL)
Median (range) 72 (45-85) Median (range) 25.8 (10.4 -63.4)
70 38 48 15.0 5 6
70 41 52 ALB (g/dL)
Gender Median (range) 3.4 (1.5 -4.3)
Male 71 90 3.5 37 59
Female 8 10 Cr (mg/dL)
PS Median (range) 0.76 (0.40 -5.26)
0 6 8 1.1 11 14
1 46 58 T-Bil (mg/dL)
2 13 16 Median (range) 0.6 (0.2 -7.2)
3 11 14 1.0 9 12
4 3 4 AST (U/L)
BI Median (range) 26 (10-251)
Median (range) 1230 (0 -3,000) 35 23 29
Clinical stage ALT (U/L)
B 5 6 Median (range) 20 (5 -164)
 74 94 40 13 17
COPD 33 42 LDH (U/L)
IP 21 27 Median (range) 278 (152-2,258)
BRA 30 38 220 56 72
OSS 15 19 ALP (U/L)
HEP 28 35 Median (range) 269 (95-1,853)
ADR 16 20 340 21 27
PUL 13 16 γ -GTP (U/L)
PLE 20 25 Median (range) 36 (10-1,264)
WBRT 39 51 60 24 31
STI 17 23 Na (mEq/L)
AHF-TRT 4 5 Median (range) 139 (118-147)
Bone radiotherapy 13 18 135 17 22
BMA 14 19 Ca (mg/dL)
No. of chemotherapy Median (range) 9.2 (6.9 -12.2)
regimens 10.2 10 17
0 3 4 CRP (mg/dL)
1 26 35 Median (range) 1.27 (0.05 -17.13)
2 16 22 0.3 58 78
3 15 20 CEA (ng/mL)
4 10 14 Median (range) 6.2 (0.5 -2,800)
5 3 4 5.0 38 51
6 1 1 Cyfra (ng/mL)
WBC count (/μL) 0 Median (range) 3.3 (1.0 -62)
Median (range) 7400 (2,000-15,700) 3.5 24 32
10,000 14 18 ProGRP (pg/mL)
Neutrophil count (/μL) Median (range) 930 (15.2 -29,200)
Median (range) 5200 (570-14,370) 81 60 81
7,500 15 21 NSE (ng/mL)
Hemoglobin (g/dL) Median (range) 47.7 (9.4 -1,670)
Median (range) 13.0 (8.6 -16.3) 16.3 55 74
12.0 21 27
PS : Performance status, BI : Brinkman index, COPD : chronic obstructive pulmonary disease, IP : Interstitial pneumonia, BRA : Brain metastasis,
OSS : Bone metastasis, HEP : Liver metastasis, ADR : Adrenal metastasis, PUL : Lung metastasis, PLE : Pleural dissemination, WBRT : Whole brain
radiation therapy, STI : stereotactic irradiation for brain, AHF-TRT : Accelerated hyperfractionated thoracic radiotherapy, BMA : Bone modifying
agents, ALB : Albumin, AST : Aspartate amino transferase, ALT : alanine amino transferase, LDH : lactate dehydrogenase, ALP : alkaline phos-
phatase, γ -GTP : γ -glutamyl transpeptidase, Na : sodium, Ca : calcium corrected for albumin, CRP : C-reactive protein, CEA : carcinoembryonic
antigen, Cyfra : cytokeratin 19 fragment, ProGRP : pro-gastrin releasing peptide, NSE : neuron specific enolase
: median (range)
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ALP, which was the most significant parameter of the liver and bili-
ary enzymes in univariate analysis, was induced to the multivariate
analysis. As a result, interestingly, only ALP was determined as a
laboratory poor prognostic factor (Table 3b). We also analyzed the
multivariate analysis using step-wise methods and confirmed that
same parameters were selected in this setting (data not shown).
These results suggested that, not only age and poor PS but also the
existence of IP as a comorbid disease is an important clinical poor
prognostic factor. Moreover, although liver metastasis was not
selected as a poor prognostic factor, it may have an impact on the
prognosis of ED-SCLC, because only the elevation of liver enzyme
was selected as a laboratory prognostic factor.
Relationship of PS and distant metastatic sites
In the multivariate analysis, the most prominent prognostic fac-
tor was poor PS, and any distant organ metastasis at diagnosis was
not determined as independent prognostic factors, indicating the
correlations between PS and each distant organ metastasis. Thus,
we finally compared PS with or without distant organ metastasis to
evaluate their correlation. Interestingly, PS in patients with liver
metastasis was significantly deteriorated compared with those
without liver metastasis (Fig. 2a), while no significant differences
were observed in other distant organ metastasis (Fig. 2b- f). These
results suggest that the existence of liver metastasis at diagnosis
deteriorates patient’s general condition, and resulted in poor prog-
nosis in ED-SCLC.
DISCUSSION
In this study, we retrospectively analyzed the prognostic factors
of ED-SCLC. In the univariate analysis, age, poor PS, IP, liver me-
tastasis, pleural dissemination, hypoalbuminemia, elevated neutro-
phil counts, hypercalcemia, and the elevations of liver metastasis
related parameters such as ALT, ALP, γ -GTP were selected as poor
prognostic factors (Table 2 and Fig. 1). In the multivariate analysis,
age, poor PS, IP and the elevation of liver and biliary enzymes were
extracted as independently significant poor prognostic factors
(Table 3). The poor PS was the most prominent prognostic factor,
and PS in patients with liver metastasis was significantly deteriorated
Table 2 The univariate analysis for overall survival
Variable Category MST(months) P -value* Variable Category
MST
(months) P -value*
Age (years) 70 16.4 0.001 ALB (g/dL) 3.5 7.4 0.001
70 8.7 3.5 16.4
Gender Male 10.3 0.716 Cr (mg/dL) 1.1 10.3 0.948
Female 14.9 1.1 17.1
PS 0-1 14.5 0.001 T-Bil (mg/dL) 1.0 11.5 0.544
2-4 4.2 1.0 14.4
Clinical stage B 9.1 0.971 AST (U/L) 35 13.2 0.113
 12.4 35 5.3
COPD Yes 9.5 0.233 ALT (U/L) 40 12.4 0.049
No 14.2 40 5.3
IP Yes 8.2 0.008 LDH (U/L) 220 13.9 0.15
No 13.6 220 8.7
BRA Yes 13.9 0.421 ALP (U/L) 340 12.7 0.011
No 9.4 340 5.3
OSS Yes 8.2 0.347 γ -GTP (U/L) 60 11.5 0.015
No 13.2 60 8.2
HEP Yes 7.4 0.041 Na (mEq/L) 135 13.6 0.83
No 13.3 135 11.5
ADR Yes 13.3 0.911 Ca (mg/dL) 10.2 11.4 0.004
No 11.4 10.2 3.0
PUL Yes 10.3 0.949 CRP (mg/dL) 0.3 14.4 0.11
No 12.7 0.3 10.3
PLE Yes 7.4 0.017 CEA (ng/mL) 5.0 13.6 0.473
No 13.6 5.0 10.3
WBC count (/μL) 10,000 12.7 0.664 Cyfra (ng/mL) 3.5 11.5 0.052
10,000 8.6 3.5 8.2
Neutrophil count (/μL) 7,500 13.3 0.005 ProGRP (pg/mL) 81 11.5 0.216
7,500 5.3 81 12.4
Haemoglobin (g/dL) 12.0 12.7 0.99 NSE (ng/mL) 16.3 17.1 0.253
12.0 9.5 16.3 12.7
Platelet count (104/μL) 15.0 2.7 0.244
15.0 11.5
MST : Median survival time
* : For the univariate analysis, MSTs were estimated by the Kaplan-Meier method, and statistical significance between survivals was assessed using
the Log-rank test. P0.05 was considered significant.
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when compared with those without liver metastasis (Fig. 2). These
results suggest that not only age, poor PS, IP but also the existence
of liver metastasis at diagnosis may have an impact on the prog-
nosis of ED-SCLC.
In this study, brain metastasis or bone metastasis, which are re-
ported as poor prognostic factors in previous studies, were not
selected as prognostic factors even in the univariate analysis. More-
over, the MSTs of the patients with brain metastasis tended to be
longer than the patients without brain metastasis. We thought that
these results were induced by the progressions of radiotherapy
techniques or bone modifying agents as mentioned in introduc-
tion. Moreover, the progressions of imaging modalities, such as
high resolution computed tomography (HRCT), magnetic reso-
nance imaging (MRI), or positron emission tomography-CT (PET-
CT), which enable early diagnosis and early treatment for the brain
and bone metastasis, partially influenced on these results. How-
ever, in contrast to the improvement of managements for brain and
bone metastasis, no specified method against the metastasis to
other organs was developed, therefore the liver metastasis and
pleural dissemination were still extracted as poor prognostic fac-
tors in the univariate analysis in this study.
In this study, liver metastasis was determined as a significant
poor prognostic factor in the univariate analysis, but not in the mul-
tivariate analysis. There seems to be some putative explanations
for the reasons of this finding. First, the numbers of patients en-
rolled in this study was small and only 28 patients with liver me-
tastasis were analyzed. Thus, further larger scale studies are re-
quired to draw definite conclusions in the future. Second, there is
Table 3 Cox’s regression analysis for overall survival
(a) Clinical parameters only
Factor Hazard ratio P -value*
Age 1.94 (1.07 -3.51) 0.029
Gender 0.69 (0.28 -1.66) 0.4
PS 2.71 (1.46 -5.05) 0.002
IP 2.21 (1.13 -4.33) 0.021
BRA 0.94 (0.52 -1.72) 0.84
OSS 1.80 (0.91 -3.58) 0.092
HEP 1.27 (0.70 -2.33) 0.43
ADR 1.30 (0.70 -2.41) 0.4
PUL 0.95 (0.45 -1.98) 0.89
PLE 1.68 (0.81 -3.47) 0.16
(b) Laboratory parameters
Factor Hazard ratio P -value*
Age 1.88 (0.91 -3.89) 0.089
Gender 1.03 (0.38 -2.81) 0.95
PS 1.58 (0.72 -3.45) 0.25
Neutro 1.36 (0.62 -2.98) 0.45
ALB 0.49 (0.22 -1.07) 0.075
ALP 2.39 (1.21 -4.72) 0.012
Ca 1.60 (0.65 -3.94) 0.3
CRP 1.07 (0.45 -2.55) 0.87
* : For the multivariate analysis, statistical significance was assessed us-
ing the Cox proportional hazards regression model. P0.05 was consid-
ered significant.
Figure 1. Kaplan-Meier estimates of the survival of patients with ED-SCLC according to several parameters which were significant in Log-rank
analysis.
(A) Age. (B) PS. (C) IP. (D) Brain metastasis. (E) Bone metastasis. (F) Liver Metastasis. (G) Pleural dissemination. (H) Neutrophil counts. (I) ALB.
(J) ALT. (K) ALP. (L) Calcium.
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a significant correlation between PS and liver metastasis. Because
of this correlation, liver metastasis might be difficult to be selected
as an independent prognostic factor. Although liver metastasis is
not extracted as a prognostic factor in the multivariate analysis, it is
clinically very important that liver metastasis deteriorates patient’s
PS, therefore, this result also emphasizes the importance of the
novel strategies against liver metastasis.
As the primary risk factor of SCLC is cigarette smoking, smoking
related lung diseases, such as COPD and/or IP, are often seen as
comorbid diseases in SCLC (30, 31). Among these comorbidities,
IP often become a problem in the treatment of SCLC. For example,
thoracic radiotherapy is contraindication, and chemotherapy and/
or infection often induce the acute exacerbation of IP which results
in the discontinuation of treatments. In this study, IP was extracted
as a poor prognostic factor in both univariate analysis and multi-
variate analysis (Table 2, 3a). These findings have significance in
clinics, and to our knowledge, this is the first report which show the
existence of IP is a significant prognostic factor of SCLC.
This study had several limitations. First, this was a retrospective
study with small number of patients. Therefore, there is a possi-
bility that our findings may not reflect of real clinics adequately. For
example, important parameters could have been missed in this
analysis. Second, this study was performed in only one institution.
To resolve these problems, we plan to increase the number of the
patients for analysis, and to demonstrate external validation by
analyzing the data in multiple hospitals. As a result, we will able to
show the more clinically significant data in the future.
In summary, we showed the significance of age, PS, and the
existence of IP in the prognosis of SCLC. Although liver metastasis
was not extracted as an independent poor prognostic factor, the
elevation of liver and biliary enzymes was significant factor in mul-
tivariate analysis, and PS in patients with liver metastasis was sig-
nificantly worsened. Therefore, liver metastasis at diagnosis may
have an impact on the prognosis of ED-SCLC. The findings of this
study suggested the importance of developing novel therapeutic
strategies against liver metastasis or interstitial pneumonia asso-
ciated with SCLC, although these may not have an impact on the
clinical managements directly at this time. On the basis of the ob-
tained findings of this study, further basic studies for the devel-
opment of novel therapies and clinical studies with the increased
number of patients in multiple institutions will improve the prog-
nosis of ED-SCLC patients in the future.
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